29,773 Vericel Corporation $VCEL Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC lessened its stake in Vericel Corporation (NASDAQ:VCEL) by 94.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,716 shares of the biotechnology company’s stock after selling 29,773 shares during the quarter. Sterling Capital Management LLC’s holdings in Vericel were worth $69,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of VCEL. BlackRock Inc. bought a new position in Vericel in the 2nd quarter valued at about $360,023,000. William Blair Investment Management LLC acquired a new position in shares of Vericel in the 2nd quarter valued at approximately $88,662,000. Bank of America Corp DE bought a new stake in shares of Vericel during the 2nd quarter worth approximately $45,210,000. Dimensional Fund Advisors LP lifted its holdings in shares of Vericel by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 844,755 shares of the biotechnology company’s stock worth $27,173,000 after acquiring an additional 29,135 shares during the period. Finally, TimesSquare Capital Management LLC bought a new stake in shares of Vericel during the 2nd quarter worth approximately $24,463,000.

Vericel Stock Up 1.4%

Shares of VCEL stock opened at $41.09 on Wednesday. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $49.32. The stock’s fifty day simple moving average is $40.51 and its 200 day simple moving average is $38.70. The firm has a market capitalization of $2.10 billion, a P/E ratio of 86.19 and a beta of 1.08.

Analyst Upgrades and Downgrades

VCEL has been the topic of several analyst reports. TD Cowen increased their price target on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Vericel in a research report on Tuesday, July 28th. Truist Financial cut their target price on Vericel from $58.00 to $52.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. Finally, Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday, July 30th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.20.

Vericel Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.